Five years after settling, GSK is again accused of breaching the Jemperli deal.
ApexOnco Front Page
Recent articles
Arcellx and AstraZeneca take centre stage.
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
